# Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

> **NCT05862337** · PHASE3 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 480 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anlotinib hydrochloride capsules, Penpulimab injection
- **DRUG:** Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo

## Key facts

- **NCT ID:** NCT05862337
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-10
- **Primary completion:** 2024-08
- **Final completion:** 2026-12
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2023-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05862337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05862337, "Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05862337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*